Suppr超能文献

除颤电击对心力衰竭患者的预后重要性。

Prognostic importance of defibrillator shocks in patients with heart failure.

作者信息

Poole Jeanne E, Johnson George W, Hellkamp Anne S, Anderson Jill, Callans David J, Raitt Merritt H, Reddy Ramakota K, Marchlinski Francis E, Yee Raymond, Guarnieri Thomas, Talajic Mario, Wilber David J, Fishbein Daniel P, Packer Douglas L, Mark Daniel B, Lee Kerry L, Bardy Gust H

机构信息

Division of Cardiology, University of Washington School of Medicine, 1959 NE Pacific St., Box 356422, Seattle, WA 98195-6422, USA.

出版信息

N Engl J Med. 2008 Sep 4;359(10):1009-17. doi: 10.1056/NEJMoa071098.

Abstract

BACKGROUND

Patients with heart failure who receive an implantable cardioverter-defibrillator (ICD) for primary prevention (i.e., prevention of a first life-threatening arrhythmic event) may later receive therapeutic shocks from the ICD. Information about long-term prognosis after ICD therapy in such patients is limited.

METHODS

Of 829 patients with heart failure who were randomly assigned to ICD therapy, we implanted the ICD in 811. ICD shocks that followed the onset of ventricular tachycardia or ventricular fibrillation were considered to be appropriate. All other ICD shocks were considered to be inappropriate.

RESULTS

Over a median follow-up period of 45.5 months, 269 patients (33.2%) received at least one ICD shock, with 128 patients receiving only appropriate shocks, 87 receiving only inappropriate shocks, and 54 receiving both types of shock. In a Cox proportional-hazards model adjusted for baseline prognostic factors, an appropriate ICD shock, as compared with no appropriate shock, was associated with a significant increase in the subsequent risk of death from all causes (hazard ratio, 5.68; 95% confidence interval [CI], 3.97 to 8.12; P<0.001). An inappropriate ICD shock, as compared with no inappropriate shock, was also associated with a significant increase in the risk of death (hazard ratio, 1.98; 95% CI, 1.29 to 3.05; P=0.002). For patients who survived longer than 24 hours after an appropriate ICD shock, the risk of death remained elevated (hazard ratio, 2.99; 95% CI, 2.04 to 4.37; P<0.001). The most common cause of death among patients who received any ICD shock was progressive heart failure.

CONCLUSIONS

Among patients with heart failure in whom an ICD is implanted for primary prevention, those who receive shocks for any arrhythmia have a substantially higher risk of death than similar patients who do not receive such shocks.

摘要

背景

因一级预防(即预防首次危及生命的心律失常事件)而接受植入式心脏复律除颤器(ICD)治疗的心力衰竭患者,日后可能会接受ICD的治疗性电击。关于此类患者接受ICD治疗后的长期预后信息有限。

方法

在829例随机分配接受ICD治疗的心力衰竭患者中,我们为811例植入了ICD。室性心动过速或心室颤动发作后发生的ICD电击被视为恰当电击。所有其他ICD电击均被视为不恰当电击。

结果

在中位随访期45.5个月期间,269例患者(33.2%)接受了至少一次ICD电击,其中128例患者仅接受恰当电击,87例仅接受不恰当电击,54例接受了两种类型的电击。在针对基线预后因素进行调整的Cox比例风险模型中,与未接受恰当电击相比,接受恰当ICD电击与随后全因死亡风险显著增加相关(风险比,5.68;95%置信区间[CI],3.97至8.12;P<0.001)。与未接受不恰当电击相比,接受不恰当ICD电击也与死亡风险显著增加相关(风险比,1.98;95%CI,1.29至3.05;P=0.002)。对于在恰当ICD电击后存活超过24小时的患者,死亡风险仍然升高(风险比,2.99;95%CI,2.04至4.37;P<0.001)。接受任何ICD电击的患者中最常见的死亡原因是进行性心力衰竭。

结论

在因一级预防而植入ICD的心力衰竭患者中,因任何心律失常接受电击的患者比未接受此类电击的类似患者死亡风险要高得多。

相似文献

1
Prognostic importance of defibrillator shocks in patients with heart failure.
N Engl J Med. 2008 Sep 4;359(10):1009-17. doi: 10.1056/NEJMoa071098.
5
Survival After Implantable Cardioverter-Defibrillator Shocks.
J Am Coll Cardiol. 2021 May 25;77(20):2453-2462. doi: 10.1016/j.jacc.2021.03.329.
6
Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT.
Eur Heart J. 2014 Jan;35(2):106-15. doi: 10.1093/eurheartj/eht451. Epub 2013 Oct 31.

引用本文的文献

4
Safety and Efficacy of Stereotactic Cardiac Radio-Ablation for Ventricular Tachycardia in Patients at High Risk of Mortality.
CJC Open. 2025 Jan 23;7(5):545-554. doi: 10.1016/j.cjco.2025.01.015. eCollection 2025 May.
5
Stellate Ganglia: A Key Therapeutic Target for Malignant Ventricular Arrhythmia in Heart Disease.
Circ Res. 2025 Apr 25;136(9):1049-1069. doi: 10.1161/CIRCRESAHA.124.325384. Epub 2025 Apr 24.
6
Long-Term Complications Related to Cardiac Implantable Electronic Devices.
J Clin Med. 2025 Mar 18;14(6):2058. doi: 10.3390/jcm14062058.
7
SGLT2i reduce arrhythmic events in heart failure patients with cardiac implantable electronic devices.
ESC Heart Fail. 2025 Jun;12(3):2125-2133. doi: 10.1002/ehf2.15223. Epub 2025 Feb 7.
8
The role of cardiac sympathetic denervation for ventricular arrhythmias: an updated systematic review and meta-analysis.
J Interv Card Electrophysiol. 2025 Mar;68(2):415-425. doi: 10.1007/s10840-025-01997-x. Epub 2025 Jan 29.
9
Outcomes in Catheter Ablation of Sustained Ventricular Tachycardia in Myocarditis Compared with Ischemic Heart Disease.
Rev Cardiovasc Med. 2025 Jan 9;26(1):25604. doi: 10.31083/RCM25604. eCollection 2025 Jan.
10
[Role of ventricular tachycardia ablation in patients with systolic heart failure].
Herzschrittmacherther Elektrophysiol. 2025 Mar;36(1):10-20. doi: 10.1007/s00399-024-01064-4. Epub 2025 Jan 22.

本文引用的文献

6
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
N Engl J Med. 2005 Jan 20;352(3):225-37. doi: 10.1056/NEJMoa043399.
7
Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.
Circulation. 2004 Dec 21;110(25):3760-5. doi: 10.1161/01.CIR.0000150390.04704.B7. Epub 2004 Dec 6.
10
The impact of arrhythmias in acute heart failure.
J Card Fail. 2004 Aug;10(4):279-84. doi: 10.1016/j.cardfail.2003.12.007.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验